natgillin/translations-raw huggingface dataset:
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses contained in the vaccine as ‘foreign’ and makes antibodies against them.
Ko otroka cepimo, imunski sistem prepozna dele bakterij in virusa v cepivu kot „tuje“ in izdela protitelesa, usmerjena proti njim.
When an injection of IDflu is given, the immune system (body's natural defences) will develop protection against flu infection.
Po injiciranju cepiva IDflu razvije imunski sistem (naravna obramba telesa) zaščito proti okužbi z gripo.
When an injection of INTANZA is given, the immune system (body's natural defences) will develop protection against flu infection.
Po injiciranju cepiva INTANZA razvije imunski sistem (naravna obramba telesa) zaščito proti okužbi z gripo.
When an invasive procedure is required, Lixiana should be stopped at least 24 hours beforehand, and appropriate caution exercised.
Če je potreben invaziven poseg, je treba prenehati z uporabo zdravila Lixiana vsaj 24 ur pred njim, med posegom pa je potrebna ustrezna mera previdnosti.
When an optimal response is obtained, a single injection of 250 micrograms of r-hCG or 5,000 IU to 10,000 IU hCG should be administered 24-48 hours after the last Pergoveris injection.
Ko je dosežen optimalni odziv, se mora v 24-48 urah po zadnji injekciji zdravila Pergoveris dati eno samo injekcijo z 250 mikrogrami r-hCG ali 5.000 i.e. do 10.000 i.e. hCG.
When an optimal response is obtained, a single injection of 250 microgramsof r-hCG or 5,000 IU to 10,000 IU hCG should be administered 24-48 hours after the last Luveris and FSH injections.
Ko dosežemo optimalni odziv, moramo v 24-48 urah po zadnji injekciji zdravila Luveris in FSH-ja dati eno samo injekcijo z 250 mikrogrami r-hCG ali s 5.000 i.e. do 10.000 i.e. hCG-ja.
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
Kadar dajemo nesteroidna protivnetna zdravila sočasno z anestezijo, ni mogoče izključiti tveganja za škodljive učinke na delovanje ledvic.
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
Pri hkratnem dajanje anestezije in nesteroidnih antiflogistikov ni izključuna potencialna nevarnost za delovanje ledvic.
When ANC increases > 1 x 109/ l resume RoActemra at 4 mg/kg and increase to 8 mg/kg as clinically appropriate
Ko se absolutno število nevtrofilcev poveča > 1 x 109/l, znova uvedite zdravilo RoActemra v odmerku 4 mg/kg in povečajte na 8 mg/kg, kot je klinično ustrezno.
When ANC increases > 1 x 109/ l resume RoActemra dosing every other week and increase to every week injection, as clinically appropriate.
Ko se absolutno število nevtrofilcev poveča > 1 x 109/l, znova uvedite zdravilo RoActemra z odmerjanjem enkrat na dva tedna in povečajte pogostnost odmerjanja na enkrat na teden, kot je klinično ustrezno.
When ANC increases to > 1 x 109/ l resume RoActemra
Ko se absolutno število nevtrofilcev poveča > 1 x 109/l, znova uvedite zdravilo RoActemra.
When and for how long to apply your Rivastigmine 3M Health Care Ltd. transdermal patch
Kdaj namestiti transdermalni obliž Rivastigmin 3M Health Care Ltd. in za koliko časa
When and how to take Eucreas
Kdaj in kako jemati zdravilo Eucreas
When and how to take Glivec
Kdaj in kako jemati zdravilo Glivec
When and how to take Icandra
Kdaj in kako jemati zdravilo Icandra
When and how to take Imatinib Accord
Kdaj in kako jemati zdravilo Imatinib Accord
When and how to take Imatinib Actavis
Kdaj in kako jemati zdravilo Imatinib Actavis
When and how to take Imatinib medac
Kdaj in kako jemati zdravilo Imatinib medac
When and how to take Imatinib Teva
Kdaj in kako jemati zdravilo Imatinib Teva
When and how to take Zomarist
Kdaj in kako jemati zdravilo Zomarist
When angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Pri sočasnem zdravljenju z antagonisti angiotenzina II in nesteroidnimi protivnetnimi zdravili (NSAID) (npr. s selektivnimi zaviralci COX-2, acetilsalicilno kislino /> 3 g/dan/ in neselektivnimi NSAID) se antihipertenzivni učinek lahko zmanjša.
When angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory medicinal products (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Sočasno jemanje antagonistov angiotenzina II in nesteroidnih protivnetnih zdravil (NSAID), npr. selektivnih zaviralcev COX-2, acetilsalicilne kisline (več kot 3 g na dan) in neselektivnih NSAID, lahko oslabi antihipertenzivni učinek.
When angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Pri sočasnem zdravljenju z antagonisti angiotenzina II in nesteroidnimi protivnetnimi zdravili (NSAID) (npr. selektivnimi COX-2 zaviralci, acetilsalicilno kislino (> 3 g/dan) in neselektivnimi NSAID) se lahko antihipertenzivni učinek zmanjša.
When angiotensin II antagonists are administered simultaneously with NSAIDs attenuation of the antihypertensive effect may occur.
Če so antagonisti angiotenzina II uporabljeni sočasno z NSAIDs, se lahko njihov antihipertenzivni učinek zmanjša.
When angiotensin II receptor antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Če se antagonisti angiotenzina II dajejo sočasno z nesteroidnimi protivnetnimi zdravili (npr. selektivnimi zaviralci COX-2, acetilsalicilno kislino (> 3 g/dan) in neselektivnimi NSAID), se lahko njihov antihipertenzivni učinek zmanjša.
When applied to a moist surface, the thrombin is activated and cuts fibrinogen up into smaller units called fibrin.
Ko ga nanesemo na vlažno površino, se trombin aktivira in pretvori fibrinogen v manjše enote, imenovane fibrini.
When applying a proposed microbiological breakpoint of I  4 g/ml, cefovecin resistance in
Ob dajanju predlaganega mikrobiološkega odmerka I ≤ 4 µg/ml, je bila rezistenca na cefovecin pri
When applying a proposed microbiological breakpoint of S  2 g/ml, no resistance to cefovecin was detected in Pasteurella multocida, Fusobacterium spp. or Porphyromonas spp. field isolates.
Ob dajanju predlaganega mikrobiološkega odmerka S ≤ 2 µg/ml, pri Pasteurella multocida, Fusobacterium spp. in Porphyromonas spp.rezistenca na cefovecin ni bila opažena.
When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1).
Odmerek se po potrebi lahko nato še nadalje povečuje po 5 mg, vendar pa ne sme preseči največjega dnevnega odmerka 30 mg (glejte poglavje 5.1).
When Aptivus/ritonavir is co-administered with telaprevir, a decrease or an increase of telaprevir exposure
Pri sočasni uporabi zdravila Aptivus/ritonavirja in telaprevirja se lahko izpostavljenost telaprevirju zmanjša ali zveča.
When aripiprazole was administered concomitantly with lamotrigine, dextromethorphan, warfarin, omeprazole, escitalopram, or venlafaxine there was no clinically important change in concentrations of these medicinal products.
Če je bil aripiprazol dan sočasno z lamotriginom, dekstrometorfanom, varfarinom, omeprazolom, escitalopramom ali venlafaksinom, se koncentracije teh zdravil niso klinično pomembneje spremenile.
When Armisarte is given with cisplatin, an ‘anti-emetic’ medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Kadar se zdravilo Armisarte daje v kombinaciji s cisplatinom, je treba pred odmerkom cisplatina ali po njem bolniku dati tudi „antiemetično“ zdravilo (za preprečevanje bruhanja) in tekočino (za preprečevanje dehidracije).
When ART naïve patients were treated with the currently approved doses of fosamprenavir/ritonavir, as for other ritonavir boosted PI regimens, the mutations described were infrequently observed.
Pri bolnikih, ki se predhodno še niso zdravili s protiretrovirusnimi zdravili, so se pri zdravljenju s trenutno priporočenimi odmerki fosamprenavirja/ritonavirja opisane mutacije pojavile redko, podobno kot pri drugih režimih zdravljenja z zaviralci proteaz z okrepitvijo z ritonavirjem.
When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebo-subtracted systolic/diastolic reductions of 15.8/10.0 mm Hg.
150 mg irbesartana in 12,5 mg hidroklorotiazida je pokazal, da se je krvni tlak v obdobju 24 ur konstantno zmanjševal in da je srednje 24 urno znižanje sistoličnega krvnega tlaka 15,8 mmHg večje kot pri uporabi placeba, diastoličnega pa za 10,0 mmHg.
When assessing the EGFR mutation status of a patient, it is important that a well-validated and robust methodology is chosen to avoid false negative or false positive determinations.
Pri določanju bolnikovega statusa mutacij EGFR je pomembno izbrati dobro validirano in robustno metodologijo, da se izognemo lažno negativnim ali lažno pozitivnim rezultatom.
When attempting to start the injection: After placing the administration system on the skin, the status light alternately flashes green and orange (no body contact) instead of remaining green.
Ko poskušate začeti injiciranje: Po namestitvi aplikacijskega sistema na kožo kontrolna lučka ne ostane zelena, ampak izmenično utripa zeleno in oranžno (ni stika s telesom).
When AUC 0-6 was adjusted by dose and body weight, a slightly higher AUC 0-6 /D/W for total CMS and total free colistin was observed in children.
Po popravku vrednosti AUC 0-6 glede na odmerek in telesno maso so pri otrocih opazili nekoliko višjo vrednost AUC 0- 6/odmerek/maso za celotni natrijev kolistimetat in celotni prosti kolistin.
When Bexsero is given to you or your child, the very common side effects (may affect more than 1 in 10 people) that you or your child may get (reported in all age groups) are: pain/tenderness at the injection site, redness of the skin at the injection site, swelling of the skin at the injection site, hardness of the skin at the injection site.
Če cepivo Bexsero prejmete vi ali vaš otrok, so zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 oseb), ki se lahko pojavijo pri vas ali vašem otroku (poročani v vseh starostnih skupinah): bolečina/občutljivost na mestu injiciranja, pordelost kože na mestu injiciranja, oteklina v koži na mestu injiciranja, zatrdlina v koži na mestu injiciranja.
When blood must be withdrawn prior to an infusion, use an administration set without a filter, then infuse Kovaltry through an injection filter.
Kadar je treba pred infundiranjem odvzeti kri, uporabite pribor brez filtra in nato infundirajte zdravilo Kovaltry skozi injekcijski filter.
When boceprevir is
Če se boceprevir uporablja
When borderline rejections were included in the primary efficacy endpoint, the rates were 26.0% and 23.9% respectively, with no statistically significant difference between the basiliximab- and placebo-treated groups (HR: 1.04, 90% CI: [0.64; 1.68]).
Če so med dogodke za primarni cilj opazovanja šteli tudi mejne zavrnitve, sta ustrezna deleža znašala 26,0 % in 23,9 %, brez statistično značilne razlike med skupinama, ki sta prejemali baziliksimab oziroma placebo (razmerje tveganj: 1,04; 90-odstotni IZ: [0,64; 1,68]).
When Bortezomib Accord is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with Bortezomib Accord.
Kadar se zdravilo Bortezomib Accord uporablja v kombinaciji z drugimi zdravili je treba prebrati Povzetke glavnih značilnosti teh zdravil pred začetkom zdravljenja z zdravilom Bortezomib Accord.
When Bortezomib Accord is given together with pegylated liposomal doxorubicin, you will receive Bortezomib Accord intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m2 is given on day 4 of the Bortezomib Accord 21-day treatment cycle as an intravenous infusion after the Bortezomib Accord injection.
Če boste prejeli zdravilo Bortezomib Accord skupaj s pegiliranim liposomskim doksorubicinom, vam bodo zdravilo Bortezomib Accord injicirali v veno ali v podkožje v 21-dnevnem krogu zdravljenja in pegilirani liposomski doksorubicin v odmerku 30 mg/m2 v obliki enourne intravenske infuzije na dan 21-dnevnega kroga zdravljenja, po injekciji zdravila Bortezomib Accord.
When Bortezomib Accord is given together with thalidomide and dexamethasone, the duration of a treatment cycle is 28 days (4 weeks).
Če jemljete zdravilo Bortezomib Accord skupaj z talidomidom in deksametazonom, traja en krog zdravljenja 28 dni (4 tedne).
When Bortezomib Hospira is given in combination with other medicinal products, refer to the Summary of Product Characteristics of these products for instructions for administration.
Pri sočasni uporabi zdravila Bortezomib Hospira z drugimi zdravili glejte povzetke glavnih značilnosti teh zdravil za navodila za odmerjanje.
When Bortezomib Hospira is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.
Pri sočasni uporabi zdravila Bortezomib Hospira z drugimi zdravili glejte povzetke glavnih značilnosti teh zdravil za dodatne kontraindikacije.
When Bortezomib Hospira is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with Bortezomib Hospira.
Kadar se zdravilo Bortezomib Hospira uporablja v kombinaciji z drugimi zdravili, je treba prebrati povzetke glavnih značilnosti teh zdravil pred začetkom zdravljenja z zdravilom Bortezomib Hospira.
When bortezomib is given together with dexamethasone, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 20 mg is given orally on days 1, 2, 4, 5, 8, 9, 11, and 12, of the bortezomib, 21-day treatment cycle.
Če boste prejeli bortezomib skupaj z deksametazonom, boste prejeli zdravilo v veno ali v podkožje v 21-dnevnem krogu zdravljenja in 20 mg deksametazona peroralno na 1., 2., 4., 5., 8., 9., 11. in 12. dan kroga zdravljenja z bortezomibom.
When bortezomib is given together with dexamethasone, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib 21-day treatment cycle.
Če jemljete bortezomib skupaj z deksametazonom, boste prejeli bortezomib v veno ali v podkožje v 21-dnevnem krogu zdravljenja in 40 mg deksametazona peroralno na 1., 2., 3., 4., 8., 9., 10. in 11. dan kroga zdravljenja z bortezomibom.
When bortezomib is given together with pegylated liposomal doxorubicin, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m2 is given on day 4 of the bortezomib 21-day treatment cycle as an intravenous infusion after the bortezomib injection.
Če boste prejeli bortezomib skupaj s pegiliranim liposomskim doksorubicinom, vam bodo bortezomib injicirali v veno ali v podkožje v 21-dnevnem krogu zdravljenja in pegilirani liposomski doksorubicin v odmerku 30 mg/m2 v obliki enourne intravenske infuzije na 4. dan 21-dnevnega kroga zdravljenja, po injekciji bortezomiba.
When bortezomib is given together with thalidomide and dexamethasone, the duration of a treatment cycle is 28 days (4 weeks).
Če jemljete bortezomib skupaj z talidomidom in deksametazonom, traja en krog zdravljenja 28 dni (4 tedne).
When Bortezomib SUN is given together with dexamethasone, you will receive Bortezomib SUN intravenously or subcutaneously as a 21-day treatment cycle.
Če boste prejeli zdravilo Bortezomib SUN skupaj z deksametazonom, vam bodo zdravilo Bortezomib SUN injicirali v veno ali v podkožje v 21-dnevnem krogu zdravljenja.
When Bortezomib SUN is given together with thalidomide and dexamethasone, the duration of a treatment cycle is 28 days (4 weeks).
Če uporabljate zdravilo Bortezomib SUN skupaj s talidomidom in deksametazonom, traja en krog zdravljenja 28 dni (4 tedne).
When bosentan is administered concomitantly with saquinavir/ritonavir, the patient’s tolerability of bosentan should be monitored.
Kadar se bosentan daje skupaj s sakvinavirjem/ritonavirjem je treba spremljati bolnikovo prenašanje bosentana.
When Canigen L4 is given to dogs the animals’ immune system recognises the bacteria as ‘foreign’ and makes defences against them.
Ko pse cepimo z zdravilom Canigen L4, njihov imunski sistem bakterije prepozna kot „tujke“ in proti njim razvije obrambo.
When CaniLeish is given to dogs the immune system recognises the proteins as ‘foreign’ and make defences against it.
Ko pes prejme cepivo CaniLeish, imunski sistem prepozna beljakovine kot „tujek“ in proti njim začne tvoriti protitelesa.
when carrying out mildly to moderately painful procedures and examinations that require the animal to be restrained or sedated and made less sensitive to pain (analgesia) but are non-invasive (do not involve breaking the skin or a body cavity). as premedication (treatment given before inducing general anaesthesia).
pri blago do zmerno bolečih posegih in pregledih, pri katerih so potrebni mirovanje in sedacija živali ter zmanjšanje občutljivosti za bolečino (analgezija), pri čemer so ti posegi in pregledi neinvazivni (ne vključujejo predrtja kože ali stene telesne votline); kot premedikacija (zdravilo, ki se daje pred uvedbo splošne anestezije).
When carrying out mildly to moderately painful procedures and examinations that require the animal to be restrained or sedated and made less sensitive to pain (analgesia).
kadar se izvajajo blago do zmerno boleči postopki in pregledi, pri katerih mora biti žival ukročena ali mirna ter manj občutljiva na bolečino (analgezija).
When caspofungin is co-administered to paediatric patients (12 months to 17 years of age) with these same inducers of metabolic enzymes (see section 4.5), a caspofungin dose of 70-mg/m2 daily (not to exceed an actual daily dose of 70 mg) should be considered.
Če se kaspofungin uporablja pri pediatričnih bolnikih (starih od 12 mesecev do 17 let) sočasno s temi induktorji presnovnih encimov (glejte poglavje 4.5), je treba razmisliti o uporabi kaspofungina v odmerku 70 mg/m2 na dan (pri čemer pa absolutni dnevni odmerek ne sme preseči 70 mg).
When censored for potentially disease modifying subsequent therapy (i.e., induction chemotherapy or hypomethylating agent) the analysis for overall survival showed a 20% reduction in the risk of death for subjects in the Dacogen arm [HR = 0.80, (95% CI: 0.64, 0.99), p- value = 0.0437)].
Po cenzuriranju podatkov zaradi nadaljnje uporabe zdravil, ki potencialno lahko spreminjajo potek bolezni (torej indukcijske kemoterapije ali hipometilirajočih sredstev), kažejo rezultati analize celotnega preživetja 20-odstotno zmanjšano tveganje za smrt v skupini bolnikov, ki so prejemali zdravilo Dacogen [razmerje tveganja = 0,80, (95-odstotni IZ: 0,64; 0,99), vrednost p = 0,0437)].
When Ceplene is first given, the patient’s blood pressure, heart rate and lung function must be monitored.
Ob prvemu dajanju zdravila Ceplene je treba pri bolniku spremljati krvni tlak, srčni utrip in delovanje pljuč.
When Ceplene is given with interleukin-2, it helps the immune system to kill the leukaemia cells that may remain in the body during remission.
Če se zdravilo Ceplene uporablja sočasno z interlevkinom-2, pomaga imunskemu sistemu uničevati levkemične celice, ki lahko ostanejo v telesu med remisijo.
When Cervarix is given for the first dose, it is recommended that Cervarix (and not another vaccine against HPV) be given for the complete vaccination course.
Po cepljenju s prvim odmerkom cepiva Cervarix priporočamo, da se cepljenje zaključi s cepivom Cervarix (in ne z drugim cepivom proti HPV).
When changing basal insulin to Tresiba, dose reduction of basal and bolus insulin needs to be considered on an individual basis, in order to minimise the risk of hypoglycaemia (see section 4.4).
Pri zamenjavi bazalnega insulina z zdravilom Tresiba je pri vsakem bolniku posebej treba presoditi o zmanjšanju odmerka bazalnega in bolusnega insulina, da se zmanjša tveganje za pojav hipoglikemije (glejte poglavje 4.4).
When changing from a progestogen-only pill (minipill)
Prehod z jemanja izključno progestogenske tabletke (mini tabletke)
When changing from a progestogen-only-method
Uporaba obliža namesto metode, pri kateri uporabljamo le progestogen
When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with ABASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast- acting insulin analogues or the dose of oral antidiabetic medicinal products).
Pri prehodu s srednjedolgo- ali dolgodelujočega insulina na zdravljenje z zdravilom ABASAGLAR utegneta biti potrebna sprememba odmerka bazalnega insulina in prilagoditev sočasnega antidiabetičnega zdravljenja (odmerek in časovni razpored dodatnih običajnih insulinov ali hitrodelujočih insulinskih analogov oz. odmerek peroralnih antidiabetikov).
When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with Lantus, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).
Pri prehodu s srednjedolgo- ali dolgodelujočega insulina na zdravljenje z zdravilom Lantus, utegneta biti potrebna sprememba odmerka bazalnega insulina in prilagoditev sočasnega antidiabetičnega zdravljenja (odmerek in časovni razpored dodatnih navadnih insulinov ali hitrodelujočih insulinskih analogov oz. odmerek peroralnih antidiabetikov).
When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with Toujeo, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).
Pri prehodu s srednjedolgo- ali dolgodelujočega insulina na zdravljenje z zdravilom Toujeo utegneta biti potrebna sprememba odmerka bazalnega insulina in prilagoditev sočasnega antidiabetičnega zdravljenja (odmerek in časovni razpored dodatnih običajnih insulinov ali hitrodelujočih insulinskih analogov oz. odmerek peroralnih antidiabetikov).
When changing from another insulin regimen to Ryzodeg, dose reduction of total insulin needs to be considered on an individual basis, in order to minimise the risk of hypoglycaemia (see section 4.4).
Pri zamenjavi insulina z zdravilom Ryzodeg je pri vsakem bolniku posebej treba presoditi o zmanjšanju celokupnega odmerka insulina, da se zmanjša tveganje za pojav hipoglikemije (glejte poglavje 4.4).
When changing patients from conventional oral hydrocortisone replacement therapy given three times daily to Plenadren, an identical total daily dose may be given.
Pri prehodu bolnikov s konvencionalnega peroralnega nadomestnega zdravljenja s hidrokortizonom, ki so ga bolniki jemali trikrat na dan, na zdravljenje z zdravilom Plenadren se lahko daje enak skupni dnevni odmerek.